Skip to main content

Table 4 Univariate and multivariate analyses of clinicopathologic parameters associated with disease-free survival

From: The prognostic value of neuromedin U in patients with hepatocellular carcinoma

Clinical parameters

Univariate analysis

Multivariate analysis

HR

95% CI

P value

HR

95% CI

P value

Sex (male vs. female)

0.914

0.560–1.492

0.720

   

Age (yrs) (≤60 vs. >60)

1.092

0.765–1.558

0.630

   

HCC family history (yes vs. no)

1.218

0.642–2.309

0.546

   

HBsAg (positive vs. negative)

0.703

0.425–1.162

0.169

   

Cirrhosis (yes vs. no)

0.916

0.635–1.320

0.636

   

Tumor number (single vs. multiple)

2.163

1.569–2.981

<0.001

   

Tumor size (cm) (≤5 vs. >5)

2.355

1.670–3.320

<0.001

1.551

1.065–2.258

0.022

Major vascular invasion (yes vs. no)

2.510

1.743–3.617

<0.001

   

Edmondson grade (I + II vs. III + IV)

1.584

1.118–2.244

0.010

1.514

1.067–2.149

0.020

TNM stage (I + II vs. III + IV)

3.077

2.240–4.225

<0.001

2.484

1.767–3.494

<0.001

Child-Pugh class (A vs. B)

1.846

1.112–3.063

0.018

1.789

1.064–3.008

0.028

PLT count (×109) (≥100 vs. <100)

2.623

1.338–5.141

0.005

   

TBIL (μmol/L) (<34.2 vs. ≥34.2)

1.373

0.819–2.301

0.229

   

ALT (U/L) (≤40 vs. >40)

1.281

0.867–1.894

0.214

   

AST (U/L) (≤37 vs. >37)

2.328

1.643–3.299

<0.001

1.775

1.225–2.572

0.002

AFP (ug/L) (≤20 vs. >20)

1.218

0.850–1.744

0.282

   

NMU peri-tumor (low vs. high group)

1.374

1.012–1.865

0.041

   

NMU intra-tumor (low vs. high group)

1.179

0.867–1.604

0.294

   
  1. Abbreviations: HR hazard ratio, CI confidence interval, HCC hepatocellular carcinoma, HBsAg hepatitis B surface antigen, TNM tumor-node- metastasis, PLT platelet, TBIL total bilirubin, ALT alanine aminotransferase, AST aspartate aminotransferase, AFP a-fetoprotein, NMU neuromedin U. It was considered to have significance when a value of p was < 0.05